Elucida Oncology develops break-through ultra small CDot platform that enables precise tumor targeting, deep tumor penetration and better tumor killing efficacity. Enables novel therapeutics that clear rapidly and efficiently from the body, reducing the potential for off- target toxicities and resulting in an improved safety profile for patients. Also enables more precise surgery of tumors. Elucida is currently enrolling patients for its first phase 1 trial and is advancing numerous solid pre-clinical progams.
Location: United States, New Jersey, South Brunswick
Employees: 11-50
Total raised: $44M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | ARTEFIN | artefin-ve... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.01.2021 | Series A | $44M | - |
Mentions in press and media 13
| Date | Title | Description |
| 15.02.2024 | Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference | MONMOUTH JUNCTION, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Onc... |
| 03.01.2023 | Elucida Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference | /EIN News/ -- MONMOUTH JUNCTION, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that management will participate at t... |
| 06.05.2022 | Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference | MONMOUTH JUNCTION, N. J. , May 06, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida On... |
| 03.03.2022 | Elucida Oncology to Present at Two Upcoming Scientific Conferences | MONMOUTH JUNCTION, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Dr. Greg Adams, Chief Scientific Officer of E... |
| 05.01.2022 | Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones | Enrolling third dose level in Phase 1/2 dose escalation study of ELU001, our lead clinical program targeting solid tumors overexpressing folate receptor alpha (FRα) Interim Phase 1 data for ELU001 in 1H22 and interim Phase 2 data in 2H22 Ge... |
| 05.01.2022 | Elucida Oncology to Present at Two Upcoming Investor Conferences | MONMOUTH JUNCTION, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Onc... |
| 05.01.2022 | Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones | Enrolling third dose level in Phase 1/2 dose escalation study of ELU001, our lead clinical program targeting solid tumors overexpressing folate receptor alpha (FRα) Interim Phase 1 data for ELU001 in 1H22 and interim Phase 2 data in 2H22 Ge... |
| 13.01.2021 | Elucida Oncology Raises $44M in Series A-1 Financing | Elucida Oncology, a Monmouth Junction, NJ-based biotechnology company pioneering the next frontier in targeted cancer therapy, closed a $44m Series A-1 financing. The backers remained undisclosed. The company intends to use the funds to con... |
| 12.01.2021 | Elucida Oncology Closes $44 Million Series A-1 Financing | MONMOUTH JUNCTION, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today it has closed a $44 million Series A-1 financing. “Over the past t... |
| 12.01.2021 | Elucida Oncology Closes $44 Million Series A-1 Financing | MONMOUTH JUNCTION, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today it has closed a $44 million Series A-1 financing. “Over the past t... |
Show more